Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R4UA
|
|||
| Drug Name |
Hu3F8 mAb
|
|||
| Indication | Neuroblastoma [ICD-11: 2D11.2] | Phase 2 | [1] | |
| Osteosarcoma [ICD-11: 2B51; ICD-9: 170] | Phase 2 | [2] | ||
| Company |
Y-mAbs Therapeutics New York, NY
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ganglioside GD2 (GD2) | Target Info | . | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02502786) Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.